KESTRA MEDICAL TECHNOLOGIES, LTD. Q1 FY26 Results
KMTSQ1 FY26 ResultsAnnounced Sep 11, 2025, 08:00 AM| Metric | Value ($ M) |
|---|---|
| Revenue | 19.37 |
| Total Income | 19.37 |
| Expenditure | 48.25 |
| PBT | -25.79 |
| Net Profit | -25.83 |
| OPM | — |
| NPM | — |
| EPS | -0.50 |
Kestra Medical Technologies Reports Q1 FY26 Revenue Up 52% to $19.4M
04 May 2026 · 4 May, 9:06 am
Summary
Kestra Medical Technologies reported a strong start to fiscal 2026, generating revenue of $19.4 million in Q1 FY26, a 52% increase compared to the prior year period. The company's gross margin expanded to 45.7%, driven by volume leverage and a higher mix of in-network patients. Kestra increased its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. GAAP net loss and comprehensive loss was $25.8 million compared to $20.3 million in the prior year period.
Key Highlights
- 1
Kestra Medical Technologies generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.
- 2
The company expanded its gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.
- 3
Kestra increased its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25.
- 4
4,205 prescriptions were written for the ASSURE® system, an increase of 51% compared to the prior year period.
- 5
GAAP net loss and comprehensive loss was $25.8 million compared to GAAP net loss and comprehensive loss of $20.3 million in the prior year period.
Management Comments
Brian Webster
We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter. We also continued to make progress on several key operational objectives, including growing the commercial organization, enhancing our revenue cycle management capabilities, and expanding gross margin. As we progress on our journey to category leadership, we remain focused on both market share capture and growing the wearable defibrillator market, while executing on our commitments to patients and their prescribers.
Informational and educational content only. Not investment advice.